Clinical trials presented at WCLC 2025 demonstrate advances in EGFR-mutated NSCLC management through combinatory strategies. Tagrisso (osimertinib) combined with chemotherapy reduced death risk by 23% over monotherapy. Similarly, ivonescimab, a PD-1/VEGF bispecific antibody, improved progression-free survival post-third-generation EGFR-TKI treatment. The ACROSS 2 Phase III trial found aumolertinib plus chemotherapy superior in patients with EGFR and tumor suppressor gene alterations. Additional data indicate benefit in continuing osimertinib beyond progression combined with chemotherapy. Together, these findings support integration of combination regimens in this molecular subtype to optimize outcomes.